Fuzaylova Ilana, Lam Chester, Talreja Om, Makaryus Amgad N, Ahern Deborah, Cassagnol Manouchkathe
College of Pharmacy and Health Sciences, 4131St. John's University, Jamaica, NY, USA.
Department of Cardiology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health, North Shore University Hospital, Manhasset, NY, USA.
J Pharm Pract. 2020 Oct;33(5):696-699. doi: 10.1177/0897190019828915. Epub 2019 Feb 18.
Sacubitril/valsartan (Entresto®) is the first commercially available angiotensin receptor neprilysin inhibitor (ARNI) approved for use in heart failure patients with a reduced ejection fraction. It is a combination drug that contains sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker. Our report outlines a case of probable ARNI-induced hyponatremia occurring in an elderly woman with heart failure with a reduced ejection fraction. According to Naranjo Adverse Drug Reaction Assessment, score indicated a likely association between patient's hyponatremia and her use of sacubitril/valsartan.
沙库巴曲缬沙坦（诺欣妥®）是首个获批用于射血分数降低的心力衰竭患者的上市血管紧张素受体脑啡肽酶抑制剂（ARNI）。它是一种复方药物，包含脑啡肽酶抑制剂沙库巴曲和血管紧张素II受体阻滞剂缬沙坦。我们的报告概述了1例射血分数降低的老年心力衰竭女性患者可能由ARNI引起低钠血症的病例。根据纳伦霍药物不良反应评估，评分表明患者低钠血症与其使用沙库巴曲缬沙坦之间可能存在关联。
